Page 14 - Pharmaceutical

Cipla receives US FDA's approval for generic Tricor tablet

Tricor (fenofibrate) tablet and generic equivalents had US sales of approximately $ 307 million for the 12 month period ending October 2016, according to IMS Health

Lonza buys gelatin capsules maker Capsugel from KKR for $ 5.5 billion

With 13 facilities, which include a hard capsule manufacturing facility in Delhi (India), Capsugel is one of the leading global players in advanced oral dosage delivery technologies

Cipla to set up manufacturing facility for pharmaceuticals in Iran

For this, the company has agreed to form a joint venture with Iran's Ahran Tejarat Company with an investment of approximately Euro 16.875 million (about Rs 120 crore)

Alkem's Ankleshwar APIs facility receives three 483 observations from US FDA

These observations were issued following an inspection conducted by US FDA at the site from December 5-9, 2016

Lonza in talks with KKR to buy Capsugel

If the deal materialises, then experts believe that it would be worth more than $ 5 billion

Natco launches generic Tamiflu capsule in US

Tamiflu oral capsules had US sales of approximately $ 403 million for twelve months ending December 2015, according to IMS Health

Glenmark launches first generic version of Zetia in US

The company and its partner, Endo, will be entitled to 180 days of generic drug exclusivity for ezetimibe, which is used for the treatment of high cholesterol

Sun Pharma to partner with Israel's Moebius Medical for osteoarthritis drug

As per the licensing deal, Sun Pharma will have worldwide commercialisation & manufacturing rights for MM-II, a candidate for the treatment of pain in osteoarthritis

Strides Shasun buys Perrigo's APIs facility in India for Rs 100 crore

The company intends to transfer all the integrated DMFs filed for captive consumption to the acquired facility, which is located in Ambernath (Maharashtra) and is US FDA-approved

PolyPeptide buys Lonza's peptides business

The acquisition will enhance PolyPeptide's manufacturing capacity of peptides, which, like proteins, are naturally occurring chains of amino acids

IVI to fund development of Inovio's MERS vaccine

International Vaccine Institute (IVI) will add technical, laboratory and financial support for clinical trials of GLS-5300, a MERS (Middle East Respiratory Syndrome) vaccine

Dipankar Bhattacharjee to head Teva's global generics business

Bhattacharjee, who has served as president and CEO of Teva Generics Europe since April 2013, succeeds Sigurdur Olafsson

Lupin receives US FDA pain killer drug

The approved product, hydrocodone bitartrate and acetaminophen tablet, is a generic equivalent of Allergan Sales LLC's Norco tablet

Lupin to market Eli Lilly's insulin analog product in India

The Mumbai-based pharma company will market and sell Eglucent, a new brand of Lilly's insulin analog Lispro, while Eli Lilly will be responsible for manufacturing and import

Lupin receives US FDA nod for sleep disorder drug armodafinil

The approved product is a generic version of Cephalon Inc's Nuvigil tablet, which recorded annual US sales of $ 515.6 million

Patheon acquires Roche's APIs manufacturing site in US

It will provide Patheon with a major APIs operation in the US capable of supporting products from clinical scale to commercial manufacturing

Sun Pharma launches first branded ophthalmic product BromSite in US

Developed by its California-based subsidiary, InSite Vision, the product is also the first bromfenac ophthalmic solution formulated in DuraSite, a polymer-based drug delivery system

Pfizer to launch new products under Corex brand

At the same time, the company will discontinue the production of the current Corex cough syrup formulation (a combination of codeine phosphate and chlorpheniramine maleate)

Johnson & Johnson in talks to acquire Actelion

Switzerland-based Actelion, a biopharmaceutical company that focuses on drugs for rare diseases, reported revenue of Swiss Francs (CHF) 2.05 billion in 2015

Sun Pharma acquires Russia's Biosintez for $ 24 million

Acquisition will enhance local manufacturing capability of Sun Pharma, which also assume a debt of approximately $ 36 million as part of this transaction, in Russia